Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 26;6(14):4122-4131.
doi: 10.1182/bloodadvances.2022007247.

Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma

Mayur Narkhede  1 , Gaurav Goyal  1 , Lauren Shea  1 , Amit Mehta  1 , Smith Giri  1   2
Affiliations

Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma

Mayur Narkhede et al. Blood Adv. .

Erratum in

Abstract

Mantle cell lymphoma (MCL) is considered incurable with the available chemoimmunotherapy approaches, and therefore, newer effective targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors are increasingly used in MCL as chronic suppressive therapy, especially in the elderly. We aimed to describe the treatment patterns in MCL at different lines of therapy with a focus on BTK inhibitor use and compare outcomes with known prognostic factors using a nationwide Flatiron Health electronic health record-derived de-identified database. We analyzed patient-level data from the period of 2011 to 2021. In this study of 4336 patients with MCL, we found that bendamustine plus rituximab chemotherapy was the most commonly used frontline regimen (42%). Maintenance rituximab or consolidative autologous stem cell transplant (ASCT) was administered to 31% of all patients. Also, for patients who received ASCT as consolidation therapy, only 34% subsequently received rituximab maintenance. BTK inhibitors were the most preferred agents in second or later lines of therapy (n = 933, 57%), followed by bortezomib, lenalidomide, and venetoclax, respectively. Among patients treated with BTK inhibitors, the median real-world overall survival (rwOS) was 35 months (95% confidence interval [CI], 27-50), 24 months (95% CI, 22-30), and 18 months (95% CI, 14-21) for first line, second line, and third or later line of therapy, respectively. Patients with a deletion 17p/TP53 mutation and blastoid variant MCL had poor outcomes; however, BTK inhibitors appeared to mitigate the negative influence of del17p/TP53-mutated MCL with a hazard ratio of 1.17 (95% CI, 0.88-1.55) on multivariable analysis.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
CONSORT flow diagram.
Figure 2.
Figure 2.
Proportion of patients receiving targeted agents for different lines of therapy.
Figure 3.
Figure 3.
K-M plots for rwOS. KM, Kaplan-Meier curves.
Figure 4.
Figure 4.
Kaplan-Meier plots for rwOS stratified by testing methods.
Figure 5.
Figure 5.
Kaplan-Meier plots for rwOS for blastoid variant MCL with and without concurrent del17p/TP53 mutation.
See this image and copyright information in PMC

References

    1. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684-1692. - PMC - PubMed
    1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443-459. - PubMed
    1. Le Gouill S, Thieblemont C, Oberic L, et al. ; LYSA Group . Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250-1260. - PubMed
    1. Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410-418. - PubMed
    1. Riedell PA, Hamadani M, Ahn KW, et al. Outcomes and utilization trends of front-line autologous hematopoietic cell transplantation for mantle cell lymphoma. Transplant Cell Ther. 2021;27(11):911.e1-911.e7. - PMC - PubMed